1. Home
  2. JNVR vs SBFM Comparison

JNVR vs SBFM Comparison

Compare JNVR & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JNVR
  • SBFM
  • Stock Information
  • Founded
  • JNVR 2018
  • SBFM 2006
  • Country
  • JNVR United States
  • SBFM United States
  • Employees
  • JNVR N/A
  • SBFM N/A
  • Industry
  • JNVR Finance: Consumer Services
  • SBFM Biotechnology: Pharmaceutical Preparations
  • Sector
  • JNVR Finance
  • SBFM Health Care
  • Exchange
  • JNVR Nasdaq
  • SBFM Nasdaq
  • Market Cap
  • JNVR N/A
  • SBFM 3.7M
  • IPO Year
  • JNVR 2023
  • SBFM N/A
  • Fundamental
  • Price
  • JNVR $0.55
  • SBFM $3.14
  • Analyst Decision
  • JNVR
  • SBFM
  • Analyst Count
  • JNVR 0
  • SBFM 0
  • Target Price
  • JNVR N/A
  • SBFM N/A
  • AVG Volume (30 Days)
  • JNVR 21.7K
  • SBFM 90.8K
  • Earning Date
  • JNVR 11-12-2024
  • SBFM 11-11-2024
  • Dividend Yield
  • JNVR N/A
  • SBFM N/A
  • EPS Growth
  • JNVR N/A
  • SBFM N/A
  • EPS
  • JNVR N/A
  • SBFM N/A
  • Revenue
  • JNVR $1,786,085.00
  • SBFM $30,481,982.00
  • Revenue This Year
  • JNVR N/A
  • SBFM $86.70
  • Revenue Next Year
  • JNVR N/A
  • SBFM $126.76
  • P/E Ratio
  • JNVR N/A
  • SBFM N/A
  • Revenue Growth
  • JNVR N/A
  • SBFM 109.82
  • 52 Week Low
  • JNVR $0.42
  • SBFM $2.42
  • 52 Week High
  • JNVR $1.84
  • SBFM $660.00
  • Technical
  • Relative Strength Index (RSI)
  • JNVR 49.64
  • SBFM 52.62
  • Support Level
  • JNVR $0.49
  • SBFM $2.85
  • Resistance Level
  • JNVR $0.62
  • SBFM $3.05
  • Average True Range (ATR)
  • JNVR 0.06
  • SBFM 0.14
  • MACD
  • JNVR -0.00
  • SBFM 0.03
  • Stochastic Oscillator
  • JNVR 58.69
  • SBFM 85.29

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Share on Social Networks: